The use of LLMs in healthcare is still quite new, so health systems want to deploy these tools in the least risky way possible. A panel of experts explained how they think health systems can do this during MedCity's INVEST conference — some of their advice included starting with deployment in nonclinical settings and partnering with incumbent vendors rather than startups.
Novartis is partnering with algorithms startup Anumana to develop a new artificial intelligence-based solution for cardiovascular diseases. The goal is to find ways to detect heart conditions years before symptoms develop in order to enable earlier intervention.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
Early detection and treatment of heart failure can greatly improve an otherwise poor prognosis. Research from Mayo Clinic suggests artificial intelligence could be used to detect the condition even when no symptoms are present.
Mayo Clinic shared results of a study showing that an AI tool developed by the system could be used to improve diagnosis of low ejection fraction, a type of heart disease. It's part of a broader push by Mayo Clinic to commercialize AI-based diagnostic tools, starting with spinout company Anumana.
Mayo Clinic struck joint ventures with two startups to develop and commercialize AI diagnostic tools. It’s part of a broader plan by Mayo Clinic to develop more AI tools to support clinical decisions.